311P PFS2 and 3 after first-line CDK4/6i in HR+/HER2- metastatic breast cancer patients based on PAM50 intrinsic subtype and treatment strategies within the SOLTI-1801 CDK-PREDICT studyP. Tolosa Ortega, E.M. Ciruelos, T. Pascual et al.|ESMO Open|2025Cited by 0